Mito-MGN

Mito-MGN (mitochondria-targeted magnolol) is a small molecule derivative of the natural polyphenol magnolol, specifically engineered to accumulate within the mitochondria of cancer cells. By leveraging the elevated mitochondrial membrane potential characteristic of malignant cells, Mito-MGN selectively disrupts mitochondrial bioenergetics. Its primary mechanism of action involves the inhibition of mitochondrial complex I (NADH:ubiquinone oxidoreductase), which suppresses oxidative phosphorylation (OXPHOS) and mitochondrial respiration. This disruption leads to an increase in reactive oxygen species (ROS) production, oxidation of mitochondrial peroxiredoxin, and the induction of mitophagy. Mito-MGN has shown significant potency in inhibiting the proliferation and invasion of melanoma cells, particularly those that have developed resistance to BRAF inhibitors through metabolic reprogramming toward an OXPHOS-dependent state.

Other names

mitochondria-targeted magnololmitochondria-targeted-magnolol